Skip to main content
CODX
NASDAQ Life Sciences

Co-Diagnostics Sets 1-for-25 Reverse Split Effective Nov. 24 to Chase Nasdaq $1.00 Bid

Tom Rudovsky · Reported by Wiseek News
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.166
Mkt Cap
$1.73M
52W Low
$0.162
52W High
$13.54
52W Position info
2.5% above low
Off High info
99% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

CODX is trading near its 52-week low of $0.162 (2.5% above the low).

Summary

Co-Diagnostics will execute a 1-for-25 reverse split effective 12:01 a.m. Mountain Time on Tuesday, November 24, 2026, with shares beginning trading split-adjusted on The Nasdaq Capital Market at market open that day under new CUSIP 189763 303, cutting shares outstanding from 13,044,465 to roughly 521,779. The Board approved the 1-for-25 ratio on November 13, 2026, and the company filed the Articles of Amendment on November 19, 2026; no fractional shares will be issued, with holders otherwise entitled to a fraction receiving one whole share in lieu of it, and stockholders owning through a bank, broker or other nominee have positions automatically adjusted and need take no further action, subject to brokers' particular processes. VStock Transfer, LLC, the transfer agent, was appointed exchange agent, and outstanding options and warrants are proportionally adjusted with a corresponding increase in exercise price per share, while the split reduces shares available for issuance under the equity incentive plans; authorized shares of Common Stock and Preferred Stock and their par value are unaffected. The stated purpose is regaining Nasdaq's $1.00 minimum bid price, and the company cautions compliance is not assured and that it may not be able to conduct equity financings in the future. This is the completion of the reverse-split authorization shareholders granted at the November 13 special meeting, following four failed quorum attempts and a court-ordered meeting. The split itself does not change equity value, but it is intended to maintain sufficient authorized shares for equity financings as needed — relevant given Q3 cash of $714,803, going-concern doubt, and the J.J. Astor convertible loan that diverts ATM proceeds to the lender. Watch whether post-split shares hold above $1.00 and whether the company taps the shelf via a 424B prospectus supplement.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — Co-Diagnostics filed the Articles of Amendment on November 19, 2026; post-split shares will trade under new CUSIP 189763 303, with about 521,779 shares outstanding.

    • Split Ratio and Approval — On November 13, 2026, the Board approved a reverse stock split ratio of 1-for-25.
    • Effective Timing — The split is effective 12:01 a.m. Mountain Time on Tuesday, November 24, 2026, with split-adjusted trading on The Nasdaq Capital Market at market open November 24, 2026; a press release states 12:01 a.m. ET on Tuesday, November 24, 2026.
    • Fractional Shares — No fractional shares will be issued; each stockholder otherwise entitled to a fractional share will receive one whole share in lieu of such fractional share, and stockholders otherwise entitled to fractional shares will have those shares rounded up to the next whole share.
    • Options and Warrants — Stock options and warrants outstanding immediately prior to the split are proportionally adjusted, with a corresponding increase in the applicable exercise price per share, in accordance with their terms.
    • Incentive Plan Shares — The reverse stock split reduces the number of shares of common stock available for issuance under the Company's equity incentive plans.
    • Exchange Agent — VStock Transfer, LLC, the Company's transfer agent, is appointed to act as exchange agent for the reverse stock split.
    • Broker-Held Shares — Stockholders owning shares via a bank, broker or other nominee have positions automatically adjusted and need take no further action, subject to brokers' particular processes.
    • Authorized Shares Purpose — The split is intended to maintain sufficient authorized shares available for issuance to allow the Company to conduct equity financings as needed; authorized Common Stock and Preferred Stock and their par value are not affected.
    • No Assurance — There is no assurance that the reverse stock split will result in maintaining Nasdaq listing compliance or that the Company will be able to conduct equity financings in the future.
    All 12 details
    • On November 13, 2026, the Board approved a reverse stock split ratio of 1-for-25.
    • Effective 12:01 a.m. Mountain Time on Tuesday, November 24, 2026; shares begin trading split-adjusted on The Nasdaq Capital Market at market open November 24, 2026.
    • No fractional shares issued; each stockholder otherwise entitled to a fractional share receives one whole share of common stock in lieu of such fractional share.
    • Stock options and warrants outstanding immediately prior to the split are proportionally adjusted, with a corresponding increase in the applicable exercise price per share, in accordance with their terms.
    • The reverse stock split reduces the number of shares of common stock available for issuance under the Company's equity incentive plans.
    • VStock Transfer, LLC, the Company's transfer agent, appointed to act as exchange agent for the reverse stock split.
    • Stockholders owning shares via a bank, broker or other nominee have positions automatically adjusted and need take no further action, subject to brokers' particular processes.
    • Press release states the Reverse Stock Split becomes effective at 12:01 a.m. ET on Tuesday, November 24, 2026.
    • Intended to maintain sufficient authorized shares available for issuance to allow the Company to conduct equity financings as needed.
    • Stockholders otherwise entitled to fractional shares will have those shares rounded up to the next whole share.
    • No assurance that the reverse stock split will result in maintaining Nasdaq listing compliance or that the Company will be able to conduct equity financings in the future.
    • The number of authorized shares of Common Stock and Preferred Stock, and the par value of such shares, shall not be affected by this amendment.

At the time of this announcement, CODX was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.16 to $13.54. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

CODX - Latest Insights

CODX
Nov 13, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.2585
Real-time Price: $0.137927 info
Change: -$0.120573 (-47%) info
Market Cap: $1.73M info
CODX
Nov 10, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.2856
Real-time Price: $0.137927 info
Change: -$0.147673 (-52%) info
Market Cap: $1.73M info
CODX
Nov 10, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.3652
Real-time Price: $0.137927 info
Change: -$0.227273 (-62%) info
Market Cap: $1.73M info
CODX
Nov 04, 2026, 4:45 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $0.3615
Real-time Price: $0.137927 info
Change: -$0.223573 (-62%) info
Market Cap: $1.73M info
CODX
Oct 26, 2026, 4:00 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.5459
Real-time Price: $0.137927 info
Change: -$0.407973 (-75%) info
Market Cap: $1.73M info